Harvard Apparatus Regenerative Technology Inc. (HRGN)
Full history for every metric is available with a Kvantra account
Harvard Apparatus Regenerative Technology Inc. (HRGN)
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 1 | 1 | - |
| Operating profit | $m | -8 | -7 | ||||||
| Net profit | $m | -5 | -8 | -6 | -9 | -8 | -7 | -7 | - |
| EPS reported | $ | -0.42 | -0.40 | ||||||
| Operating cashflow per share | $ | -0.23 | -0.21 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.23 | -0.21 | ||||||
| Free cash flow | $m | -4 | -4 | ||||||
| Net debt | $m | -1 | 0 | ||||||
| Book value equity | $m | 1 | -1 | ||||||
| Book value per share | $ | 0.06 | -0.08 | ||||||
| Number of shares | m | 16.52 | 17.58 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 28.75 | -22.04 | ||||||
| P/S LTM | x | 43.17 | 35.38 | ||||||
| P/FCF LTM | x | -7.94 | -8.36 | ||||||
| EV/EBITDA LTM | x | -4.33 | -4.45 | ||||||
| EV/Sales LTM | x | 41.53 | 31.43 | ||||||
| Earnings Yield LTM | % | -22.60% | -25.03% | ||||||
| FCF Yield | % | -12.60% | -11.96% | ||||||
| Quality | |||||||||
| ROE | % | -649.86% | -2019.03% | ||||||
| ROIC | % | -6.07% | +9.62% | ||||||
| Operating margin | % | -10.82% | -8.22% | ||||||
| Gross margin | % | +8.24% | -53.90% | ||||||
| FCF/Sales | % | -543.75% | -423.17% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -19.24 | -5.64 | ||||||
| Net Debt/EBITDA | x | 0.17 | -0.04 | ||||||
| EBIT/Net interest | x | -952.38 | -784.33 | ||||||
| Net debt/market cap | % | +0.65% | +2.42% | ||||||
| Net debt/Equity | x | -1.09 | -0.11 | ||||||
| Gross debt/equity | x | 0.19 | -0.47 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Harvard Apparatus Regenerative Technology Inc. (HRGN)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free